Stay updated on Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial page.

Latest updates to the Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial page
- Check7 days agoChange DetectedThe Study Record Dates now display 'Results Submitted' instead of 'No Results Posted', indicating that results have been submitted.SummaryDifference0.1%

- Check13 days agoChange DetectedAn update adds a new footer revision tag 'Revision: v3.4.2' and removes an outdated 'Notice' about government funding as well as the prior 'Revision: v3.4.1' tag. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check21 days agoChange DetectedA site-wide notice about government funding and NIH Clinical Center operations was added, and the site revision was updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check28 days agoChange DetectedUI updates include showing the glossary toggle and new metadata labels (Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data, and Revision: v3.4.0), while the corresponding older labels (Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, and Revision: v3.3.4) were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check42 days agoChange DetectedRevision: v3.3.4 appears in the page footer replacing the previous v3.3.3. The update does not alter study details or eligibility information.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded a Locations section listing Texas as the study site. Removed the HHS Vulnerability Disclosure footer and updated the page revision to v3.3.3.SummaryDifference0.2%

Stay in the know with updates to Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial page.